The latest price target for Addex Therapeutics (NASDAQ: ADXN) was reported by HC Wainwright & Co. on June 23, 2022. The analyst firm set a price target for $0.00 expecting ADXN to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Addex Therapeutics (NASDAQ: ADXN) was provided by HC Wainwright & Co., and Addex Therapeutics downgraded their neutral rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Addex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Addex Therapeutics was filed on June 23, 2022 so you should expect the next rating to be made available sometime around June 23, 2023.

While ratings are subjective and will change, the latest Addex Therapeutics (ADXN) rating was a downgraded with a price target of $0.00 to $0.00. The current price Addex Therapeutics (ADXN) is trading at is $0.38, which is out of the analyst’s predicted range.

The latest price target for Addex Therapeutics (NASDAQ: ADXN) was reported by HC Wainwright & Co. on June 23, 2022. The analyst firm set a price target for $0.00 expecting ADXN to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Addex Therapeutics (NASDAQ: ADXN) was provided by HC Wainwright & Co., and Addex Therapeutics downgraded their neutral rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Addex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Addex Therapeutics was filed on June 23, 2022 so you should expect the next rating to be made available sometime around June 23, 2023.

While ratings are subjective and will change, the latest Addex Therapeutics (ADXN) rating was a downgraded with a price target of $0.00 to $0.00. The current price Addex Therapeutics (ADXN) is trading at is $0.38, which is out of the analyst’s predicted range.

The latest price target for Addex Therapeutics (NASDAQ: ADXN) was reported by HC Wainwright & Co. on June 23, 2022. The analyst firm set a price target for $0.00 expecting ADXN to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Addex Therapeutics (NASDAQ: ADXN) was provided by HC Wainwright & Co., and Addex Therapeutics downgraded their neutral rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Addex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Addex Therapeutics was filed on June 23, 2022 so you should expect the next rating to be made available sometime around June 23, 2023.

While ratings are subjective and will change, the latest Addex Therapeutics (ADXN) rating was a downgraded with a price target of $0.00 to $0.00. The current price Addex Therapeutics (ADXN) is trading at is $0.38, which is out of the analyst’s predicted range.

The latest price target for Addex Therapeutics (NASDAQ: ADXN) was reported by HC Wainwright & Co. on June 23, 2022. The analyst firm set a price target for $0.00 expecting ADXN to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Addex Therapeutics (NASDAQ: ADXN) was provided by HC Wainwright & Co., and Addex Therapeutics downgraded their neutral rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Addex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Addex Therapeutics was filed on June 23, 2022 so you should expect the next rating to be made available sometime around June 23, 2023.

While ratings are subjective and will change, the latest Addex Therapeutics (ADXN) rating was a downgraded with a price target of $0.00 to $0.00. The current price Addex Therapeutics (ADXN) is trading at is $0.38, which is out of the analyst’s predicted range.

The latest price target for Addex Therapeutics (NASDAQ: ADXN) was reported by HC Wainwright & Co. on June 23, 2022. The analyst firm set a price target for $0.00 expecting ADXN to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Addex Therapeutics (NASDAQ: ADXN) was provided by HC Wainwright & Co., and Addex Therapeutics downgraded their neutral rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Addex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Addex Therapeutics was filed on June 23, 2022 so you should expect the next rating to be made available sometime around June 23, 2023.

While ratings are subjective and will change, the latest Addex Therapeutics (ADXN) rating was a downgraded with a price target of $0.00 to $0.00. The current price Addex Therapeutics (ADXN) is trading at is $0.38, which is out of the analyst’s predicted range.

The latest price target for Addex Therapeutics (NASDAQ: ADXN) was reported by HC Wainwright & Co. on June 23, 2022. The analyst firm set a price target for $0.00 expecting ADXN to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Addex Therapeutics (NASDAQ: ADXN) was provided by HC Wainwright & Co., and Addex Therapeutics downgraded their neutral rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Addex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Addex Therapeutics was filed on June 23, 2022 so you should expect the next rating to be made available sometime around June 23, 2023.

While ratings are subjective and will change, the latest Addex Therapeutics (ADXN) rating was a downgraded with a price target of $0.00 to $0.00. The current price Addex Therapeutics (ADXN) is trading at is $0.38, which is out of the analyst’s predicted range.

The latest price target for Addex Therapeutics (NASDAQ: ADXN) was reported by HC Wainwright & Co. on June 23, 2022. The analyst firm set a price target for $0.00 expecting ADXN to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Addex Therapeutics (NASDAQ: ADXN) was provided by HC Wainwright & Co., and Addex Therapeutics downgraded their neutral rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Addex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Addex Therapeutics was filed on June 23, 2022 so you should expect the next rating to be made available sometime around June 23, 2023.

While ratings are subjective and will change, the latest Addex Therapeutics (ADXN) rating was a downgraded with a price target of $0.00 to $0.00. The current price Addex Therapeutics (ADXN) is trading at is $0.38, which is out of the analyst’s predicted range.

The latest price target for Addex Therapeutics (NASDAQ: ADXN) was reported by HC Wainwright & Co. on June 23, 2022. The analyst firm set a price target for $0.00 expecting ADXN to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Addex Therapeutics (NASDAQ: ADXN) was provided by HC Wainwright & Co., and Addex Therapeutics downgraded their neutral rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Addex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Addex Therapeutics was filed on June 23, 2022 so you should expect the next rating to be made available sometime around June 23, 2023.

While ratings are subjective and will change, the latest Addex Therapeutics (ADXN) rating was a downgraded with a price target of $0.00 to $0.00. The current price Addex Therapeutics (ADXN) is trading at is $0.38, which is out of the analyst’s predicted range.